-
Patient Rating
5.0 /5( out of 146 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
March 01, 2025HUNTSMAN CANCER CENTERMary Steinbach is professional, knowledgeable and personable. Wonderful to work with.
February 28, 2025HUNTSMAN CANCER CENTERMary Steinbeck is an amazing APRN, in taking care of me as a patient. Mary has always been amazing because she cares and shows it to the patient. She is very knowledgeable and helpful in letting the patient know what is going on in a language that is easily understood.
February 11, 2025HUNTSMAN CANCER CENTERWe love Mary. She is intelligent, professional, listens, makes you feel at ease to share concerns. She shows interest in our family and our life outside the clinic. We are grateful for her part in my care team. .
February 03, 2025HUNTSMAN CANCER CENTERMary Steinbach is first rate: professional, thorough, yet caring and friendly.
February 02, 2025HUNTSMAN CANCER CENTERMary is an outstanding APRN and a very nice person.
January 15, 2025HUNTSMAN CANCER CENTERExcellent job
January 01, 2025HUNTSMAN CANCER CENTERShe is wonderful very caring and compassionate explaining everything so you feel very comfortable with what you are being told . She is amazing and we appreciate her very much
December 15, 2024HUNTSMAN CANCER CENTERMary Steinbeck is an amazing care professional. She takes time with me and is never in a hurry. She is very knowledgeable and explains my medical issues so that I can understand them. Mary is amazing and I'm thankful when I see her.
December 12, 2024HUNTSMAN CANCER CENTERI've known Mary for several years now. She is an excellent APRN who provides great care to her patients.
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Advanced Practice Clinician
Academic Divisions Hematology & Hematologic Malignancies
Education history
Doctoral Training Nursing - Ïã½¶ÊÓÆµ of Utah DNP Undergraduate Nursing - Loyola Ïã½¶ÊÓÆµ of Chicago BSN Undergraduate Environmental Geoscience - Boston College B.S. Selected Publications
Journal Article
- Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, Spivak AM, Steinbach M, Blaylock RC, Avila SV, Hankey KG, Martins TB, Slev PR, Mannuel HD, Sajadi M, Rapoport AP, Atanackovic D (2020). Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv, 4(19), 4864-4868. ()
- Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D (2017). Elotuzumab as a novel anti-myeloma immunotherapy. Hum Vaccin Immunother, 13(8), 1751-1757. ()
- Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T (2016). Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology, 5(11), e1217374. ()
- Couriel DR, Ricker H, Steinbach M, Lee CJ (2016). Neurologic Manifestations of Blood Dyscrasias. Hematol Oncol Clin North Am, 30(4), 723-31. ()
- Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Krger N, Luetkens T, Atanackovic D (2015). CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother, 11(7), 1606-11. ()
Review
- Hoshina Y, Galli J, Wong KH, Kovacsovics T, Steinbach M, Salzman KL, McNally JS, Lancaster E, Paz Soldn MM, Clardy SL (2022). GABA-A Receptor Encephalitis After Autologous Hematopoietic Stem Cell Transplant forMultiple Myeloma: Three Cases and Literature Review. [Review]. Neurol Neuroimmunol Neuroinflamm, 9(6). ()
- Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13, 20406207221100659. ()
- Steinbach M, Richards T, Faiman B (2017). Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients. [Review]. Semin Oncol Nurs, 33(3), 254-264. ()
Letter
- Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Krger N, Luetkens T (2019). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. [Letter to the editor]. Leukemia, 34(1), 317-321. ()
- Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Krger N, Luetkens T, Atanackovic D (2015). Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. [Letter to the editor]. Blood Cancer J, 5, e285. ()
-
News & Podcasts
Huntsman Cancer Institute News
( out of 146 reviews )